Mobile

The long-term antibody persistence of GSK Biologicals’ MenACWY-TT vaccine (GSK134612) versus Mencevax ACWY in healthy ado-lescents and adults and booster response to MenACWY-TT vaccine administered at...

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-005639-10

The long-term antibody persistence of GSK Biologicals’ MenACWY-TT vaccine (GSK134612) versus Mencevax ACWY in healthy ado-lescents and adults and booster response to MenACWY-TT vaccine administered at 10 years post-primary vaccination

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To evaluate the long-term persistence of the serum bactericidal (antibody) titers induced by MenACWY-TT vaccine as compared to Mencevax ACWY when administered to individuals 11-55 years of age in terms of the percentage of subjects with Neisseria meningitidis serogroup A (MenA), serogroup C (MenC), serogroup W-135 (MenW-135), and serogroup Y (MenY) titers ≥ 1:8, ≥ 1:128 and Geometric mean titres (GMTs) as measured by a serum bactericidal assay using rabbit complement (rSBA)

Critère d'inclusion

  • prevention of invasive disease caused by Neisseria meningitidis serogroups A, C, W-135, and Y in healthy subjects aged 11 to 55 years of age)

Liens